Serial PSMA PET/MR images will be collected at baseline, 6 months, and 2 years to characterize the imaging response of prostate cancer to treatment and potentially identify imaging biomarkers (including pharmacokinetics, radiomics, and quantitative PET and mpMRI metrics) that predict for 5-year DFS (Table 4). The gene discussed is FOLH1; the disease is prostate cancer.